Literature DB >> 22341619

Perfusion magnetic resonance imaging: comparison of semiologic characteristics in first-pass perfusion of brain tumors at 1.5 and 3 Tesla.

Natacha Mauz1, Alexandre Krainik, Irène Tropres, Laurent Lamalle, Elodie Sellier, Omer Eker, Florence Tahon, Jean-François Le Bas, Sylvie Grand.   

Abstract

OBJECTIVES: To investigate whether using 3 Tesla (T) instead of 1.5T modifies the data obtained from first-pass perfusion in relation to the quantitative values of cerebral blood volume (CBV) and estimation of micro-vascular leakage (MVL). To describe the differences in data in the setting of neuro-oncology cases and propose explanations based on the discrepancies.
MATERIAL AND METHODS: In total, 21 patients presenting an intracranial intra-axial space-occupying lesion underwent two MRI explorations, one at 1.5T and another at 3T, including a first-pass perfusion sequence using sequence parameters, defined by the manufacturer Philips. Using a gamma variate analysis, the ratio of cerebral blood volume (rCBV) in tumor, peritumoral, and normal appearing areas was first assessed. After a global analysis, a subgroup analysis was conducted according to the rCBV value measured at 1.5T. Lastly, MVL was assessed based on the signal intensity recorded above baseline after the passage of the contrast medium.
RESULTS: At 3T, compared to 1.5T data that are currently the reference, rCBV was constantly and significantly over-evaluated (P=0.0041 for all tumors), while MVL was constantly and significantly under-evaluated (P<0.0001 for all tumors). DISCUSSION: The increase in magnetic field strength along with the associated modifications in sequence parameters led to variations in rCBV and MVL when measured using first-pass perfusion. In some cases, such as lymphomas, there was a loss of diagnostic information. It therefore appears necessary to optimize the acquisition parameters to allow for radiologic semiology to become relevant again.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22341619     DOI: 10.1016/j.neurad.2011.12.004

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  6 in total

1.  Imaging of gliomas at 1.5 and 3 Tesla - A comparative study.

Authors:  Lambros Tselikas; Raphaëlle Souillard-Scemama; Olivier Naggara; Charles Mellerio; Pascale Varlet; Edouard Dezamis; Julien Domont; Frédéric Dhermain; Bertrand Devaux; Fabrice Chrétien; Jean-François Meder; Johan Pallud; Catherine Oppenheim
Journal:  Neuro Oncol       Date:  2014-12-18       Impact factor: 12.300

2.  Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Authors:  Zachary S Kelm; Panagiotis D Korfiatis; Ravi K Lingineni; John R Daniels; Jan C Buckner; Daniel H Lachance; Ian F Parney; Rickey E Carter; Bradley J Erickson
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-26

3.  Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas.

Authors:  T B Nguyen; G O Cron; K Perdrizet; K Bezzina; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J Sinclair; R E Thornhill; C Foottit; B Zanette; I G Cameron
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-30       Impact factor: 3.825

4.  The basics of diffusion and perfusion imaging in brain tumors.

Authors:  Panagiotis Korfiatis; Bradley Erickson
Journal:  Appl Radiol       Date:  2014-07-04

5.  Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.

Authors:  J Khalifa; F Tensaouti; L Chaltiel; J-A Lotterie; I Catalaa; M P Sunyach; D Ibarrola; G Noël; G Truc; P Walker; N Magné; M Charissoux; S Ken; P Peran; I Berry; E Cohen-Jonathan Moyal; A Laprie
Journal:  Eur Radiol       Date:  2016-02-02       Impact factor: 5.315

6.  Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.

Authors:  Margaux Roques; Isabelle Catalaa; Magali Raveneau; Justine Attal; Aurore Siegfried; Jean Darcourt; Christophe Cognard; Nicolas Menjot de Champfleur; Fabrice Bonneville
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.